BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: An open, randomised, parallel-group phase II/III trial

Health Technology Assessment

Volumn 20, Issue 49, 2016, Pages 1-107

  Butler, Karina ^a   Inshaw, Jamie ^b   Ford, Deborah ^b   Bernays, Sarah ^c   Scott, Karen ^b   Kenny, Julia ^b,d   Klein, Nigel ^d   Turkova, Anna ^b   Harper, Lynda ^b   Nastouli, Eleni ^e   Paparini, Sara ^c   Choudhury, Rahela ^b   Rhodes, Tim ^c   Babiker, Abdel ^b   Gibb, Diana ^b  

^a Department of Radiology   (Ireland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; BENZOXAZINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; APPENDICITIS; ARTICLE; BRONCHIECTASIS; CD4 LYMPHOCYTE COUNT; COLLAPSE; DEATH; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAINTNESS; GASTROENTERITIS; GENE MUTATION; GYNECOMASTIA; HEADACHE; HEMIPARESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIPODYSTROPHY; LIPOHYPERTROPHY; MEASLES; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SIDE EFFECT; SPONTANEOUS ABORTION; SUICIDAL IDEATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; ADOLESCENT; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; VIRAL LOAD; YOUNG ADULT;

EID: 84978977491     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20490     Document Type: Article

References (63)

1. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003;327:1019. http://dx.doi.org/10.1136/bmj.327.7422.1019.
2. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Rockville, MD: National Institutes of Health; 2008.
3. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2010 Revision. URL: http://apps.who.int/iris/ bitstream/10665/44379/1/9789241599764_eng.pdf
4. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013. URL: www.who.int/hiv/pub/guidelines/arv2013/download/en
5. Foster C, Judd A, Tookey P, Tudor-Williams G, Dunn D, Shingadia D, et al. Young people in the UK and Ireland with perinatally acquired HIV: the paediatric legacy for adult services. AIDS Patient Care STDS 2008;23:159–66. http://dx.doi.org/10.1089/apc.2008.0153.
6. Fiese BH, Everhart RS. Medical adherence and childhood chronic illness: family daily management skills and emotional climate as emerging contributors. Curr Opin Pediatr 2006;18:551–7. http://dx.doi.org/10.1097/01.mop.0000245357.68207.9b
7. Rianthavorn P, Ettenger RB. Medication non-adherence in the adolescent renal transplant recipient: a clinician’s viewpoint. Pediatr Transplant 2005;9:398–407. http://dx.doi.org/10.1111/j.1399-3046.2005.00358.x
8. Smith BA, Shuchman M. Problem of nonadherence in chronically ill adolescents: strategies for assessment and intervention. Curr Opin Pediatr 2005;17:613–18. http://dx.doi.org/10.1097/01.mop.0000176443.26872.6e
9. Bangsberg DR, Kroetz DL, Deeks SG. Adherence–resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007;4:65–72. http://dx.doi.org/10.1007/s11904-007-0010-0.
10. Casado JL, Sabido R, Perez-Elias MJ, Antela A, Oliva J, Dronda F, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antivir Ther 1999;4:157–61.
11. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000;50:1599–605. http://dx.doi.org/10.1016/S0277-9536(99)00468-2.
12. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000;30(Suppl. 2):177–84. http://dx.doi.org/10.1086/313855.
13. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564–73. http://dx.doi.org/10.7326/0003-4819-146-8-200704170-00007.
14. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30. http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00004.
15. Reddington C, Cohen J, Baldillo A, Toye M, Smith D, Kneut C, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000;19:1148–53. http://dx.doi.org/10.1097/00006454-200012000-00005.
16. Wagels T, Amiet R, Battegay M, Guex AC, Opravil M, Vernazza PL. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. Swiss Med Wkly 2004;134:678–80.
17. Gross R, Yip B, Lo Re V III, Wood E, Alexander CS, Harrigan PR, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006;194:1108–14. http://dx.doi.org/10.1086/507680.
18. Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, et al. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J 2007;26:61–7. http://dx.doi.org/10.1097/01.inf.0000250625.80340.48.
19. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005;159:764–70. http://dx.doi.org/10.1001/archpedi.159.8.764.
20. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003;22:56–62. http://dx.doi.org/10.1097/00006454-200301000-00015.
21. Gibb D, Compagnucci A, Green H, Lallemant M, Saidi Y, Ngo-Giang-Huong N, et al. Treatment interruption in children with chronic HIV-infection: the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. J Int AIDS Soc 2008;11(Suppl. 1):O21. http://dx.doi.org/10.1186/1758-2652-11-S1-O21.
22. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283–96. http://dx.doi.org/10.1056/NEJMoa062360.
23. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233–44. http://dx.doi.org/10.1056/NEJMoa0800971.
24. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006;194:623–32. http://dx.doi.org/10.1086/506364.
25. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003;17:F33–F37. http://dx.doi.org/10.1097/00002030-200310170-00001.
26. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005;40:594–600. http://dx.doi.org/10.1086/427695.
27. Smith RJ. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc Biol Sci 2006;273:617–24. http://dx.doi.org/10.1098/rspb.2005.3352.
28. Cohen C, Colson A, Morris A, Alberts L, Sheble-Hall A, Hussey S, et al. The FOTO Study 48 Week Results: Viral Suppression Can Be Maintained When Antiretrovirals are Taken Five Consecutive Days on, and Two Days Off each Week. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24–27 July 2005.
29. Cohen C, Colson A, Pierone G, DeJesus E, Kinder F, Elion R, et al. The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy. J Int AIDS Soc 2008;11:O19. http://dx.doi.org/10.1186/1758-2652-11-S1-O19.
30. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLOS ONE 2010;5:e10307. http://dx.doi.org/10.1371/journal.pone.0010307.
31. Reynolds S, Kityo C, Ssali S, Hallahan C, Mwebesa D, Mbamanya F, et al. A Randomized, Controlled, Non-inferiority Trial of Two Short Cycle Intermittent Regimens Compared to Continuous Antiretroviral Therapy for the Treatment of Chronic HIV Infection in Uganda. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, 25–28 October 2008.
32. Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, et al. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses 2009;25:555–61. http://dx.doi.org/10.1089/aid.2008.0203.
33. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretroviral therapy. AIDS 2007;21:1673–82. http://dx.doi.org/10.1097/QAD.0b013e3281c61394.
34. Frampton JE, Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006;66:1501–12; discussion 13–14. http://dx.doi.org/10.2165/00003495-200666110-00012.
35. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59–62. http://dx.doi.org/10.1097/00002030-199905280-00001.
36. Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008;46:1601–8. http://dx.doi.org/10.1086/587657.
37. Dorrell J. Being Young and HIV Positive: The Experiences of Young People Living with HIV Since Birth: A Research Study in Progress. Alive and Kicking: Growing up with HIV. National Conference held by the Children & Young People HIV Network, London, UK, 16 November 2007.
38. Machin D, Campbell M, Fayes P, Pinol A. Sample Size Tables for Clinical Studies. 2nd edn. Blackwell Science; 1997.
39. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013;21.
40. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010;24:231–41. http://dx.doi.org/10.1097/QAD.0b013e328333d343.
41. Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, et al. The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLOS ONE 2013;8:e76582. http://dx.doi.org/10.1371/journal.pone.0076582.
42. Bernays S, Rhodes T, Jankovic Terzic K. Embodied accounts of HIV and hope: using audio diaries with interviews. Qual Health Res 2014;24:629–40. http://dx.doi.org/10.1177/1049732314528812.
43. Strauss AL, Corbin JM. Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Newbury Park, CA: Sage Publications; 1990.
44. Charmaz K. Constructing Grounded Theory. London: Sage; 2006.
45. Butler K. ART with Weekends off Is Noninferior to Continuous ART in Young People on EFV + 2NRTI. Conference on Retroviruses and Opportunistic Infections 2015. URL: www. croiwebcasts.org/console/player/25558?mediaType=slideVideo& (accessed 14 March 2016).
46. Butler K. Pediatric Update BREATHER Study. Conference on Retroviruses and Opportunistic Infections 2015. Seattle, WA, USA, 23–26 February2015.
47. Deacon H. Towards a sustainable theory of health-related stigma: lessons from the HIV/AIDS literature. J Community Appl Soc Psychol 2006;16:418–25. http://dx.doi.org/10.1002/casp.900.
48. Goffman E. Stigma: Notes on the Management of Spoiled Identity. Englewood Cliffs, NJ: Prentice-Hall; 1963.
49. Link BG, Phelan JC. Conceptualizing stigma. Ann Rev Sociol 2001;27:363–85. http://dx.doi.org/10.1146/annurev.soc.27.1.363.
50. Cavalcante GI, Capistrano VL, Cavalcante FS, Vasconcelos SM, Macedo DS, Sousa FC, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci 2010;120:739–45. http://dx.doi.org/10.3109/00207454.2010.520541.
51. Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother 2014;69:1742–7. http://dx.doi.org/10.1093/jac/dku058.
52. Persson A, Newman C. Potency and vulnerability: troubled ‘selves’ in the context of antiretroviral therapy. Soc Sci Med 2006;63:1586–96. http://dx.doi.org/10.1016/j.socscimed.2006.04.001.
53. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008;22:2371–80. http://dx.doi.org/10.1097/QAD.0b013e328315cdd3.
54. Winston A, Amin J, Clarke A, Else L, Amara A, Owen A, et al. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect Dis 2015;60:1026–32.
55. Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 2014;3:e03821. http://dx.doi.org/10.7554/eLife.03821.
56. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41:4531–6. http://dx.doi.org/10.1128/JCM.41.10.4531-4536.2003.
57. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLOS Pathog 2013;9:e1003398. http://dx.doi.org/10.1371/journal.ppat.1003398.
58. Kawuma R, Bernays S, Siu G, Rhodes T, Seeley J. ‘Children will always be children’: exploring perceptions and experiences of HIV-positive children who may not take their treatment and why they may not tell. Afr J AIDS Res 2014;13:189–95. http://dx.doi.org/10.2989/16085906.2014.927778.
59. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care 2013;25:400–14. http://dx.doi.org/10.1080/09540121.2012.712667.
60. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS 2007;21:271–81. http://dx.doi.org/10.1097/QAD.0b013e328011cb20.
61. Bernays S, Seeley J, Rhodes T, Mupambireyi Z. What am I ‘living’ with? Growing up with HIV in Uganda and Zimbabwe. Sociol Health Illn 2015;37:270–83. http://dx.doi.org/10.1111/1467-9566.12189.
62. Bernays S, Jarrett P, Kranzer K, Ferrand RA. Children growing up with HIV infection: the responsibility of success. Lancet 2014;383:1355–7. http://dx.doi.org/10.1016/S0140-6736(13)62328-4.
63. World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. 2015. URL: http://apps.who.int/iris/bitstream/10665/186275/1/ 9789241509565_eng.pdf.